title: Novel Targeted Therapies for Esophagogastric Cancer.
abstract: Gastroesophageal cancer (GEC) remains a major cause of cancer-related mortality worldwide. Although the incidence of distal gastric adenocarcinoma (GC) is declining in the United States, proximal esophagogastric junction adenocarcinoma (EGJ) is increasing in incidence. GEC, including GC and EGJ, is treated uniformly in the metastatic setting. Overall survival in the metastatic setting remains poor. Molecular characterization of GEC has identified mutations and copy number variations, along with other oncogenes, biomarkers, and immuno-oncologic checkpoints that may serve as actionable therapeutic targets. This article reviews these key aberrations, their impact on protein expression, therapeutic implications, and clinical directions within each pathway.
authors.affiliation: Section of Hematology/Oncology, University of Chicago Comprehensive Cancer Center, 900 E 57th St, Suite 7128, Chicago, IL 60637, USA.
authors.forename: Steven B
authors.initials: SB
authors.lastname: Maron
authors.affiliation: Section of Hematology/Oncology, University of Chicago Comprehensive Cancer Center, 900 E 57th St, Suite 7128, Chicago, IL 60637, USA. Electronic address: dcatenac@medicine.bsd.uchicago.edu.
authors.forename: Daniel V T
authors.initials: DV
authors.lastname: Catenacci
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D000970:Antineoplastic Agents; D056915:DNA Copy Number Variations; D018572:Disease-Free Survival; D004938:Esophageal Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D004943:Esophagogastric Junction / Q000201:enzymology / Q000473:pathology; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods*; D009367:Neoplasm Staging; D019859:Proto-Oncogene Proteins c-met; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; D019859:Proto-Oncogene Proteins c-met
keywords: EGFR; Esophagogastric junction cancer; FGFR2; Gastric cancer; Gastroesophageal adenocarcinoma; HER2; MET; VEGFR2